Mary Wilson
Well-known member
In Press, Journal Pre-proof
What are journal pre-proofs?
Journal pre-proofs are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication. They have undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but are not yet definitive versions of record.
Available online 11 July 2024, e34497
https://doi.org/10.1016/j.heliyon.2024.e3449
Soroush Najdaghi [SUP]1[/SUP], Delaram Narimani Davani [SUP]1[/SUP], Mohammadreza Hashemian [SUP]2[/SUP], Narges Ebrahimi [SUP]1[/SUP] [SUP]3[/SUP]
Abstract
Background
The COVID-19 pandemic has been linked to neurological complications, including Cerebellitis. This study aims to investigate the clinical features, and consequences of Cerebellitis following COVID-19 infection, informing medical management strategies.
Methods
A systematic search was conducted through PubMed, Web of Science, Embase, ProQuest, and Cochrane databases from January 2018 to 12[SUP]th[/SUP] September 2023, on cases post-COVID-19. Demographics, clinical characteristics, and diagnostic techniques were analyzed using descriptive statistics. Chi-Square tests assessed associations between diagnoses and treatments, with visualizations including heatmaps and scatter plots.
Results
After the final Screening, the analysis of 18 cases revealed Cerebellitis post-COVID-19 spanned 9 countries, predominantly from the USA (27.8%), with a mean patient age of 40.1 years (±24.6). Males comprised 94.4% of cases. Common underlying conditions included hypertension (22.2%) and diabetes (11.1%). Neurological symptoms presented on average 15.15 ± 12.7 days post-COVID-19 infection. A moderate negative correlation (r = -0.358) was observed between age and symptom onset. Blood and CSF biomarkers showed weak correlations with symptom onset intervals. Treatment efficacy varied, with most cases achieving symptom-free outcomes. The Chi-Square test for diagnosis-treatment associations yielded a p-value of 0.089, and for follow-up outcomes, a p-value of 0.283, indicating no significant statistical associations.
Conclusion
This systematic review highlights increased reports of Cerebellitis in males in their fourth decade of life, with the highest comorbidities being vascular diseases. Marker assessments show a decrease in CSF protein in half of patients, along with complete recovery following combination treatment with antivirals and steroids in acute Cerebellitis.
https://www.sciencedirect.com/science/article/pii/S2405844024105282
What are journal pre-proofs?
Journal pre-proofs are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication. They have undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but are not yet definitive versions of record.
Available online 11 July 2024, e34497
https://doi.org/10.1016/j.heliyon.2024.e3449
Soroush Najdaghi [SUP]1[/SUP], Delaram Narimani Davani [SUP]1[/SUP], Mohammadreza Hashemian [SUP]2[/SUP], Narges Ebrahimi [SUP]1[/SUP] [SUP]3[/SUP]
Abstract
Background
The COVID-19 pandemic has been linked to neurological complications, including Cerebellitis. This study aims to investigate the clinical features, and consequences of Cerebellitis following COVID-19 infection, informing medical management strategies.
Methods
A systematic search was conducted through PubMed, Web of Science, Embase, ProQuest, and Cochrane databases from January 2018 to 12[SUP]th[/SUP] September 2023, on cases post-COVID-19. Demographics, clinical characteristics, and diagnostic techniques were analyzed using descriptive statistics. Chi-Square tests assessed associations between diagnoses and treatments, with visualizations including heatmaps and scatter plots.
Results
After the final Screening, the analysis of 18 cases revealed Cerebellitis post-COVID-19 spanned 9 countries, predominantly from the USA (27.8%), with a mean patient age of 40.1 years (±24.6). Males comprised 94.4% of cases. Common underlying conditions included hypertension (22.2%) and diabetes (11.1%). Neurological symptoms presented on average 15.15 ± 12.7 days post-COVID-19 infection. A moderate negative correlation (r = -0.358) was observed between age and symptom onset. Blood and CSF biomarkers showed weak correlations with symptom onset intervals. Treatment efficacy varied, with most cases achieving symptom-free outcomes. The Chi-Square test for diagnosis-treatment associations yielded a p-value of 0.089, and for follow-up outcomes, a p-value of 0.283, indicating no significant statistical associations.
Conclusion
This systematic review highlights increased reports of Cerebellitis in males in their fourth decade of life, with the highest comorbidities being vascular diseases. Marker assessments show a decrease in CSF protein in half of patients, along with complete recovery following combination treatment with antivirals and steroids in acute Cerebellitis.
https://www.sciencedirect.com/science/article/pii/S2405844024105282